Aidoc, which develops AI-based tools for radiologists to analyze CT scans and X-rays, has raised a $110M Series D, bringing its total funding to about $250M
Aidoc is on quite the hot streak. Aidoc is on quite the hot streak. Just about two months after racking up its ninth FDA clearance …
Context & Ripple Effects
Aidoc's raise closes a fast-widening loop: the company went from a $27M Series B in 2019 to this $110M Series D in just over three years, with a $66M General Catalyst-led round in between. The description notes it comes about two months after Aidoc's ninth FDA clearance, making regulatory approvals the visible engine behind the valuation climb.
The later coverage confirms the trajectory held: Aidoc went on to raise successive $150M rounds — one bringing its total to $370M and another, a Series E taking total funding to $520M — with General Catalyst, Square Peg, NVIDIA's NVentures, and four major U.S. health systems eventually joining the cap table.
First-order effects
- Aidoc gains roughly $110M of runway to scale its nine-times-cleared CT and X-ray analysis tools across more hospital radiology departments immediately after the raise.
- Rival radiology-AI vendors now face a competitor holding both the deepest clearance portfolio in its cohort and about $250M of cumulative backing.
Second-order effects
- The follow-on rounds show the investor base widening beyond venture capital: NVIDIA's NVentures and four U.S. health systems joining by 2025 signals hospitals and compute suppliers converting from customers into shareholders.
- Competitors without comparable FDA clearance counts are pushed toward either acquisition or their own larger raises to keep pace on the metric buyers can verify.
Third-order effects
- If clearance count keeps functioning as the primary moat, clinical imaging AI consolidates around a few platform vendors whose regulatory track record compounds with each round, squeezing point-solution startups out of hospital procurement.
- Strategic capital from health systems and chipmakers inside these rounds points toward clinical AI financing becoming an infrastructure play, where distribution through hospitals matters as much as model performance.
The trend: Radiology AI is consolidating into ever-larger platform rounds, with accumulated FDA clearances serving as the asset that unlocks each successive tranche of capital.